leisure time -WSS

leisure time

author：knowledge 2025-08-12 08:27:56 - browse：149

The removal of small amounts of brain tissue from desperately ill patients, done as part of a Mount Sinai research project, triggered alarm bells at the Food and Drug Administration and has raised broader questions about the scientific and ethical justification for live-brain research. Journalist and STAT contributor Katherine Eban joins “The Readout LOUD” podcast to discuss the results of a two-year investigation.

Also on this week’s episode, we discuss Novartis’ effort to acquire MorphoSys, and the latest news on Eli Lilly and Novo Nordisk’s blockbuster obesity drugs with Elaine Chen, the newest member of STAT’s biotech reporting team.

For more on what we cover, here’s STAT’s investigation into the Mount Sinai brain-tissue research project; here’s exclusive reporting on the MorphoSys drug at the center of the Novartis acquisition, and Adam Feuerstein’s take on where it might run off the rails; and here’s STAT’s reporting on Novo Nordisk and its weight loss drug Wegovy.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： Kellogg’s is going to war over Mexico’s nutrition label rules

WSS

As obesity drug market grows, telehealth companies court payers

Republicans love RFK Jr. What's that tell us about health in 2024?

Drugmakers bet big on mRNA for cancer. Why's Biden going in?

What past blockbusters can tell us about future of Wegovy and other weight loss medicines

Abortion policy in the spotlight at Republican debate

DeSantis wants to import drugs. Biden’s FDA blasted his plan

focus

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

explore

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

How the first Native Hawaiian psychiatrist helped diversify medicine

BioMarin wins approval for gene therapy to treat hemophilia A

STAT Summit: GSK CEO on pharma giant's new direction

George Santos makes 1st court appearance after pleading not guilty to 13 counts

FDA warns J&J's Abiomed: We will regulate your software

Wildfire smoke exposes gaps in outdoor worker protections

HHS leader on health, climate change and biopharma emissions

Walensky prepares to leave CDC — and Congress — behind

Eli Lilly expects to double planned employment in Boston center

focus

Health officials lay out plans to cope with respiratory virus season

What past blockbusters can tell us about future of Wegovy and other weight loss medicines

Studies point to risks of excluding people with obesity from drug trials

Roche's accidental data boosts hopes for anti

Medicare reduced heart disease by changing how it pays doctors

Trans patients at the end of life deserve respect and dignity

hotspot

entertainment

explore

focus